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Abstract  The  small  bowel  is  affected  in  the  vast  majority  of  patients  with  Crohn’s  Disease  (CD).
Small bowel  capsule  endoscopy  (SBCE)  has  a  very  high  sensitivity  for  the  detection  of  CD-related
pathology,  including  early  mucosal  lesions  and/or  those  located  in  the  proximal  segments  of
the small  bowel,  which  is  a  major  advantage  when  compared  with  other  small  bowel  imaging
modalities.  The  recent  guidelines  of  European  Society  of  Gastrointestinal  Endoscopy  (ESGE)  and
European  Crohn’s  and  Colitis  Organisation  (ECCO)  advocate  the  use  of  validated  endoscopic
scoring indices  for  the  classiﬁcation  of  inﬂammatory  activity  in  patients  with  CD  undergoing
SBCE, such  as  the  Lewis  Score  or  the  Capsule  Endoscopy  Crohn’s  Disease  Activity  Index  (CECDAI).
These scores  aim  to  standardize  the  description  of  lesions  and  capsule  endoscopy  reports,
contributing  to  increase  inter-observer  agreement  and  enabling  a  stratiﬁcation  of  the  severity
of the  disease.  On  behalf  of  the  Grupo  de  Estudos  Português  do  Intestino  Delgado  (GEPID)  --
dy  Group,  we  aimed  to  summarize  the  general  principles  and  clinical
oscopic  scoring  systems  for  SBCE  in  the  setting  of  CD,  covering  thePortuguese Small  Bowel  Stu
applications  of  current  end∗ Corresponding author.
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topic  of  suspected  CD  as  well  as  the  evaluation  of  disease  extent  (with  potential  prognostic  and
therapeutic  impact),  evaluation  of  mucosal  healing  in  response  to  treatment  and  evaluation  of
post-surgical  recurrence  in  patients  with  previously  established  diagnosis  of  CD.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Scores  Endoscópicos  na  Avaliac¸ão  da  Actividade  da  Doenc¸a de  Crohn  em  Enteroscopia
por  Cápsula:  Princípios  e  Aplicac¸ões  Actuais
Resumo  O  intestino  delgado  encontra-se  envolvido  pela  doenc¸a  na  maioria  dos  pacientes  com
Doenc¸a de  Crohn  (DC).  A  enteroscopia  por  cápsula  (EC)  apresenta  uma  elevada  sensibilidade  na
detecc¸ão de  lesões  relacionadas  com  a  DC,  incluindo  as  lesões  superﬁciais  mais  precoces  e/ou
localizadas no  segmentos  proximais  do  intestino  delgado,  o  que  representa  uma  clara  mais-
valia comparativamente  com  os  demais  exames  imagiológicos  do  intestino  delgado.  As  recentes
recomendac¸ões da  ESGE  (European  Society  of  Gastrointestinal  Endoscopy)  e  da  ECCO  (European
Crohn’s and  Colitis  Organisation)  recomendam  a  utilizac¸ão  dos  scores  endoscópicos  validados
para a  classiﬁcac¸ão  da  actividade  inﬂamatória  em  doentes  com  DC  submetidos  a  EC,  nomeada-
mente o  Score  de  Lewis  ou  o  CECDAI  (Capsule  Endoscopy  Crohn’s  Disease  Activity  Index).  Estes
scores permitem  uniformizar  a  descric¸ão  das  lesões  e  os  relatórios  em  EC,  contribuindo  para
uma melhoria  da  concordância  entre  observadores  e  possibilitando  a  estratiﬁcac¸ão  da  gravidade
da doenc¸a.  Em  nome  do  GEPID  (Grupo  de  Estudos  Português  do  Intestino  Delgado  -  Portuguese
Small Bowel  Study  Group),  os  autores  pretendem  sumariar  neste  documento  os  princípios  gerais
e as  aplicac¸ões  clínicas  actuais  dos  scores  endoscópicos  em  EC  no  contexto  da  DC,  incluindo  quer
a suspeita  de  DC,  quer  a  avaliac¸ão  da  extensão  da  doenc¸a  (com  potencial  impacto  prognóstico
e na  decisão  terapêutica),  avaliac¸ão  da  cicatrizac¸ão  da  mucosa  em  resposta  ao  tratamento  e
avaliac¸ão da  recorrência  pós-cirúrgica  em  doentes  com  um  diagnóstico  prévio  de  DC.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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The  small  bowel  is  affected  in  up  to  80%  of  patients
with  Crohn’s  Disease  (CD).1 Small  bowel  capsule  endoscopy
(SBCE)  may  contribute  to  establish  the  diagnosis  in  patients
with  suspected  CD,  often  being  the  next  step  after  an  initial
non-diagnostic  ileocolonoscopy,  if  the  patient  has  no  history
of  occlusive  symptoms,  suspected  stricturing  or  penetrating
disease.  The  very  high  sensitivity  of  SBCE,  inclusively  for  the
detection  of  early  superﬁcial  lesions  and/or  those  located
in  the  proximal  segments  of  the  small  bowel,  is  a  major
advantage  in  the  diagnostic  evaluation  of  patients  with  sus-
pected  CD,  when  compared  with  other  small  bowel  imaging
modalities.2,3
The  recent  guidelines  of  ESGE4 and  ECCO1 recommend
the  use  of  validated  endoscopic  scoring  indices  for  the
classiﬁcation  of  inﬂammatory  activity  in  patients  with  CD
undergoing  SBCE,  such  as  the  Lewis  Score5 or  the  Cap-
sule  Endoscopy  Crohn’s  Disease  Activity  Index  (CECDAI).6
These  scores  aim  to  standardize  the  description  of  lesions
and  capsule  endoscopy  reports,  based  on  a  structured
terminology,7 thus  providing  a  reproducible  methodology  for
interpretation  and  estimation  of  endoscopic  activity,  while
contributing  for  a  higher  inter-observer  agreement.  More-
over,  these  scores  quantify  objectively  the  inﬂammatory
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Cctivity  and  enable  a  stratiﬁcation  of  the  severity  of  the
isease.  On  behalf  of  the  Grupo  de  Estudos  Português  do
ntestino  Delgado  (GEPID)  --  Portuguese  Small  Bowel  Study
roup,  this  manuscript  aims  to  summarize  the  general  prin-
iples  and  current  applications  of  the  available  endoscopic
coring  systems  for  SBCE  in  the  setting  of  CD.
.  Lewis Score
o  calculate  the  Lewis  Score,  the  small  bowel  is  ﬁrst  divided
nto  three  equal  parts  (tertiles)  based  on  capsule  transit
ime  from  the  ﬁrst  duodenal  image  to  the  ﬁrst  cecal  image.
or  each  tertile,  a subscore  is  determined  based  on  the
xtension  and  distribution  of  oedema  (Fig.  1),  as  well  as  the
umber,  size  and  distribution  of  ulcers  (Fig.  2).  The  Lewis
core  results  of  the  sum  of  the  worst  affected  tertile  plus
he  score  of  stenosis  (Fig.  3);  stenoses  are  evaluated  consid-
ring  the  entire  length  of  the  small  bowel,  independently  of
he  division  in  tertiles  --  Table  1.
The  Lewis  Score  has  been  recently  validated  for
se  in  clinical  practice.8 Although  its  calculation  seems
npractical,  a  software  has  been  developed  to  enable
ts  automatic  calculation,  which  has  been  incorporated
nto  the  RAPID  READER® workstation  of  PillCam® capsules.
ut-off  values  have  been  devised  to  grade  and  classify  small
38  B.  Rosa  et  al.
Table  1  Lewis  Score.
Number  Extent  Descriptors
Villous  appearance
(worst-affected  tertile)
Normal  --  0 ≤10%  --  8  Single  --  1
Oedematous  --  1  11--50%  --  12  Patchy  --  14
>50%  --  20  Diffuse  --  17
Ulcer (worst-affected  tertile) None  --  0  ≤10%  --  5  <1/4  --  9
Single --  3  11--50%  --  10  1/4--1/2  --  12
2--7 --  5  >50%  --  15  >1/2  --  18
≥8 --  10  (percentage  of  the  frame
occupied  by  the  largest  ulcer)
ocupada
Stenosis (whole  study) None  -- 0 Non-ulcerated  -- 2 Traversed  --  7
Single -- 14 Ulcerated  -- 24 Not  traversed  -- 10
Multiple  --  20
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iLewis Score = tertile with highest score (resulting of oedema and 
owel  inﬂammatory  activity,  as  follows:  Lewis  Score  <135
orresponds  to  a  normal  examination  or  non-signiﬁcant
nﬂammation;  Lewis  Score  ≥135  and  <790  corresponds  to
ild  inﬂammation;  and  a  Lewis  Score  ≥790  corresponds  to
oderate  to  severe  activity.
. Niv score or Capsule Endoscopy Crohn’s
isease Activity Index (CECDAI)
he  CECDAI  evaluates  three  endoscopic  parameters:  inﬂam-
ation  (A,  0--5  points),  extent  of  disease  (B,  0--3  points)
nd  strictures  (C,  0--3  points),  both  for  the  proximal  and
istal  segments  of  the  small  bowel  based  on  the  transit
ime  of  the  capsule.  The  ﬁnal  score  is  calculated  by  adding
he  two  segmental  scores:  proximal  ([A1  ×  B1]  +  C1)  +  distal
[A2  ×  B2]  +  C2)  --  Table  2.
Figure  1  Villous  edema.
t
t
is) plus score of stenosis for the entire small bowel.
The  CECDAI  has  been  validated  in  a  prospective  mul-
icentre  trial.9 Currently,  there  is  no  software  available
or  its  automatic  calculation;  however,  its  calculation  is
uite  easy,  thus  the  CECDAI  might  eventually  be  more  intu-
tive  and  preferable  to  the  Lewis  Score  for  physicians  not
sing  PillCam® capsules.  No  cut-off  of  inﬂammatory  severity
ave  been  validated  for  the  CECDAI,  however  the  val-
es  of  3.8  and  5.8  have  been  pointed  as  approximately
orresponding  to  the  135  and  790  cut-offs  of  the  Lewis
core,  respectively.10 The  correlation  of  endoscopic  activ-
ty  indices  with  clinical  activity  scores,  as  well  as  serum
r  faecal  inﬂammatory  markers,  is  globally  poor.11 Faecal
alprotectin,  which  is  usually  considered  as  an  accurate  non-
nvasive  marker  of  intestinal  inﬂammation,  has  been  shown
o  correlate  more  closely  with  the  Lewis  Score  than  with
he  CECDAI.10 This  correlation,  however,  is  only  moderate12;
ndeed,  while  the  Lewis  Score  performs  relatively  well  in
Figure  2  Aphthous  ulcer.
Endoscopic  Scores  for  Evaluation  of  Crohn’s  Disease  Activity  at  S
Figure  3  Ulcerated  stricture.
Table  2  CECDAI  (Niv  Score).
A.  Inﬂammation  score
0  =  None
1  =  Oedema/hyperemia/denudation  (mild  to  moderate)
2 =  Oedema/hyperemia/denudation  (severe)
3 =  Bleeding,  exudate,  aphthae,  erosion,  ulcer  <0.5  cm
4 =  Ulcer  0.5--2  cm,  pseudopolyp
5 =  Large  ulcer  >2  cm
B. Extent  of  disease  score
0  =  No  disease
1 =  Focal  disease  (single  segment)
2 =  Patchy  disease  (2--3  segments)
3 =  Diffuse  disease  (>3  segments)
C. Stricture  score
0  =  None
1  =  Single-passed
2  =  Multiple-passed
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T3  =  Obstruction  (non-passage)
CECDAI = proximal (A1 × B1 + C1) + distal (A2 × B2 + C2).
describing  the  paucity  of  small  bowel  inﬂammation  at  levels
of  faecal  calprotectin  <100  g/g,  at  higher  levels  it  seems  to
have  little  or  no  correlation,  which  means  that  patients  may
still  beneﬁt  of  capsule  endoscopy  to  assess  for  small  bowel
lesions  activity  and  extension.
4. Practical clinical applications4.1.  Suspected  Crohn’s  disease
Small  bowel  capsule  endoscopy  (SBCE)  has  a  very  high  neg-
ative  predictive  value  in  patients  with  suspected  Crohn’s
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isease  (CD)  and  non-diagnostic  ileocolonoscopy,  such  that
hen  the  capsule  is  negative,  a  diagnosis  of  CD  can  be  con-
dently  excluded  in  up  to  96%  of  cases.13 Conversely,  the
etection  of  lesions  which  are  suggestive  of  CD  is  usually  a
ey  element  to  establish  the  diagnosis,  if  there  is  a  consis-
ent  clinical  context  and  if  non-steroidal  anti-inﬂammatory
rugs  (NSAIDs)  consumption  has  been  adequately  excluded
or  at  least  one  month  prior  to  the  capsule.14 However,  it
s  important  to  underline  that  endoscopic  ﬁndings  are  non-
peciﬁc,  no  single  lesion  is  pathognomonic  of  CD,  and  there
s  no  cut-off  value  of  any  endoscopic  scoring  system  above
hich  the  diagnosis  can  be  ﬁrmly  established;  indeed,  the
cores  are  not  discriminative,  since  they  grade  inﬂammatory
ctivity  independently  from  its  aetiology.  Nonetheless,  some
tudies  have  shown  that  small  bowel  CD  is  unlikely  when  the
ewis  Score  at  SBCE  is  under  135.8,14,15 Alternative  diagnoses
uch  as  Behc¸et’s Disease,  tuberculosis,  intestinal  lymphoma
r  vasculitis  should  also  be  considered  and  excluded  when-
ver  in  doubt;  in  some  cases,  deep  enteroscopy  may  be
aluable  to  further  characterize  and  take  biopsies  of  the
esions  previously  identiﬁed  by  the  capsule,  although  this
eems  not  to  be  routinely  necessary.1,4 The  criteria  indi-
ated  by  the  International  Conference  on  Capsule  Endoscopy
ICCE)16 aim  to  optimise  the  adequate  selection  of  candi-
ates  for  SBCE  among  those  patients  with  clinical  suspicion
f  CD.  In  fact,  in  order  to  avoid  an  overdiagnosis  of  CD  it  is
mportant  that  the  interpretation  of  the  lesions  detected  at
BCE  takes  into  account  the  pre-test  probability  of  CD,  which
ccording  to  the  above  mentioned  ICCE  criteria  should  be
ased  on  a  conjunction  of  clinical,  analytical  and/or  imaging
uggestive  features.
.2.  Established  Crohn’s  disease
n  patients  with  previously  known  CD,  the  initial  evaluation
f  the  small  bowel  should  be  performed  with  cross  sec-
ional  imaging  such  as  CT  or  MR  enterography  (CTE  or  MRE),
o  allow  for  a  transmural  assessment  of  disease  activity,
nabling  the  identiﬁcation  and  characterization  of  strictu-
es,  as  well  as  any  evidence  of  extra-luminal  disease  and
omplications  such  as  ﬁstulae  or  abscesses.1 SBCE  may  be
seful  in  some  speciﬁc  clinical  scenarios  in  established  CD;
owever,  it  should  be  preceded  by  small  bowel  cross  sec-
ional  imaging  and/or  a  patency  capsule  to  minimize  the
isk  of  capsule  retention.
.2.1.  Investigation  of  persistent  symptoms
he  very  high  sensitivity  of  SBCE,  even  for  subtle  mucosal
esions,  may  help  to  determine  if  symptoms  such  as  abdom-
nal  pain  or  persistent  diarrhoea  are  in  relation  with  CD
ctivity,  or  may  be  otherwise  attributable  to  other  concur-
ent  diagnoses,  such  as  irritable  bowel  syndrome,  poor
bsorption  of  bile  acids,  exocrine  pancreatic  insufﬁciency
r  bacterial  overgrowth,  among  others.17
.2.2.  Evaluation  of  disease  extent
he  existence  of  extensive  small  bowel  involvement  and/or
roximally  located  lesions  are  both  poor  prognostic  factors
n  CD;  such  ﬁndings  may  inﬂuence  therapeutic  decisions,
amely  by  triggering  an  earlier  initiation  of  immunosup-
ressive  medication  in  CD.18--22 Some  recent  studies  have
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ointed  to  the  existence  of  proximal  small  bowel  lesions
n  up  to  50%  of  patients  with  CD,  and  in  many  cases  those
re  missed  by  prior  small  bowel  imaging.19,21 Thus,  per-
orming  a  SBCE  should  be  considered  at  diagnosis  if  the
linician  considers  that  the  ﬁnding  of  new  lesions  in  the  small
owel,  not  evident  in  prior  cross  sectional  imaging,  could
nﬂuence  treatment  decision.  In  a  recent  study,21 patients
ith  a  previous  diagnosis  of  CD  were  submitted  to  SBCE;
he  endoscopic  ﬁndings  directly  triggered  a  therapeutic
scalation  with  initiation  of  immunosuppressive  treatment,
specially  when  lesions  were  located  in  the  upper  seg-
ents  of  the  small  bowel  (6%,  36%  and  45%  of  patients
ith  non-signiﬁcant,  mild  and  moderate-to-severe  lesions,
espectively).  In  another  study,  treatment  was  intensiﬁed
fter  SBCE  in  14.5%,  48.1%  and  87.1%  of  patients  with  Lewis
core  <135,  Lewis  Score  135--790  and  Lewis  Score≥790,
espectively.11
.2.3.  Evaluation  of  mucosal  healing
BCE  enables  the  longitudinal  assessment  of  small  bowel
ucosal  healing,  which  is  an  important  endpoint  of  treat-
ent  efﬁcacy  in  CD.  The  use  of  validated  endoscopic  scores,
uch  as  the  Lewis  Score  or  the  CECDAI,  may  be  particularly
nteresting  in  this  setting,  by  enabling  an  objective  quan-
iﬁcation  of  the  evolution  of  inﬂammatory  activity,  although
tandard  criteria  of  mucosal  improvement  and  mucosal  heal-
ng  are  yet  to  be  established.  In  a  recent  prospective
tudy,  symptomatic  and  biochemical  response  to  treatment
ppeared  to  be  mirrored  by  endoscopic  remission  in  only  42%
f  patients  with  active  small  bowel  CD.23 Although  there  are
urrently  no  formal  recommendations  for  the  assessment  of
ucosal  healing  with  SBCE  in  clinical  practice,  some  groups
ave  already  started  exploring  this  issue,  and  it  is  becoming
n  interesting  topic  for  future  investigation.23--25
.2.4.  Evaluation  of  post-surgical  recurrence
leocolonoscopy,  with  routine  assessment  of  the  Rutgeerts
core,  remains  the  gold  standard  for  the  evaluation  of  post-
urgical  recurrence  in  CD.  The  percentage  of  agreement
etween  ileocolonoscopy  and  SBCE  for  the  detection  of
esions  in  the  neo-terminal  ileum  has  been  widely  variable
n  the  literature,26,27 and  the  prognostic  value  of  the  differ-
nt  grades  of  inﬂammatory  activity  detected  by  the  capsule
s  currently  unknown;  moreover,  although  the  capsule  may
etect  more  lesions  in  the  upper  small  bowel  in  a  signiﬁcant
roportion  of  these  patients,  its  clinical  signiﬁcance  and
rognostic  value  are  currently  a  matter  of  debate,  requiring
urther  investigation.
. Conclusions
BCE  is  a  useful  diagnostic  examination,  either  for  the  diag-
osis  and  follow-up  of  patients  with  CD.  The  routine  use  of
uantitative  endoscopic  indices  of  severity  of  inﬂammatory
ctivity  has  been  encouraged  by  scientiﬁc  societies,  as  it
ay  contribute  to  improve  the  interpretation  of  lesions,
educing  inter-observer  variability  and  enabling  solid
omparative  data  analysis  between  different  patients  and
etween  different  studies.  Thus,  it  seems  very  important
hat  the  use  of  a  validated  endoscopic  scoring  index  should
e  systematically  considered  in  future  studies,  potentially
1B.  Rosa  et  al.
nﬂuencing  in  a  near  future  our  practical  approach  either
or  diagnosis,  staging,  prognostic  evaluation,  therapeutic
ecision  and  follow-up  of  patients  with  CD.
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